31.20 -4.49 (-12.58%)

68,912 XNAS Volume

High volume+loss today

XNAS 25 Mar, 2025 5:30 PM (EDT)

Board Meeting
The next board meeting for Sanara MedTech Inc is on 26 Mar 2025 for the purpose of Sanara MedTech Inc Fourth Quarter Earnings Conference Call for 2024 See details

Sanara MedTech Inc Key Metrics

Select
All financials are in USD Million and price data in USD
VIEW MORE
Medium Financial Strength
38.9 / 100
Expensive Valuation
9.7 / 100
Technically Neutral
49.3 / 100
Expensive Performer These stocks are with medium quality and mid-range technical aspects. However, their financials make them little expensive so choose the right moment to buy them. View Similar Embed DVM

Sanara MedTech Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25501000150Actual RevenueAvg. Estimate
Hit

Sanara MedTech Inc's Revenue was higher than average estimate 2 times in past 2 years

EPS forecast

Current EPS
-0.5
Avg. Estimate
-1.1
Low Estimate
-1.1
High Estimate
-1
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 111.5% in FY24

Consensus Recommendation

2 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Buy1Strong Buy

The consensus recommendation from 2 analysts for Sanara MedTech Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Sanara MedTech Inc Stock Analysis

Sanara MedTech Inc stock analysis with key metrics, changes, and trends.

Sanara MedTech Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$64.99 M3.79%positive

Annual Revenue rose 3.79%, in the last year to $64.99 M. Its sector's average revenue growth for the last fiscal year was 8.56%.

Annual Net Profit$4.3 M47.35%positive

Annual Net Profit rose 47.35% in the last year to $4.3 M. Its sector's average net profit growth for the last fiscal year was 4.22%.

Price to Earning Ratio-32.61-negative

Price to Earning Ratio is -32.61, which is negative.

Stock Price$31.20-16.6%negative

Stock Price fell 16.6% and underperformed its sector by 24.07% in the past year.

Quarterly Revenue$21.67 M35.24%positive

Quarterly Revenue rose 35.24% YoY to $21.67 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

Quarterly Net profit$2.86 M169.51%negative

Quarterly Net profit fell 169.51% YoY to $2.86 M. Its sector's average net profit growth YoY for the quarter was 28.52%.

Debt to Equity Ratio0.26-positive

Debt to Equity Ratio of 0.26 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-9.93 %-9.93%negative

Return on Equity(ROE) for the last financial year was -9.93%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding9.39 %0.06%positive

Mutual Fund Holding increased by 0.06% in the last quarter to 9.39.

Interest Coverage Ratio-8.33-negative

Interest Coverage Ratio is -8.33, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding11.20 %0%neutral

Institutional Holding remained the same in the last quarter at 11.2%.

VIEW LESS


Loading data..

Sanara MedTech Inc - Company Profile

What does Sanara MedTech Inc do?

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.

Sanara MedTech Inc Management structure

All Gross Remunerations are in USD
Mr. Michael D. McNeil
Chief Accounting Officer and Chief Administrative Officer
-
2025
Gross Remuneration
Year
Ms. Elizabeth B. Taylor
Chief Financial Officer
-
2025
Gross Remuneration
Year

Sanara MedTech Inc Board of directors

All Gross Remunerations are in USD
Mr. Ronald T. Nixon
Executive Chairman of the Board and Chief Executiv
-
2024
Gross Remuneration
Year
Mr. James W. Stuckert
Director Emeritus
-
2024
Gross Remuneration
Year
Mr. Keith G. Myers
Director
-
2024
Gross Remuneration
Year

Sanara MedTech Inc FAQ

How is Sanara MedTech Inc today?
Sanara MedTech Inc today is trading in the red, and is down by -12.58% at 31.20.
Sanara MedTech Inc is currently trading down -12.58% on an intraday basis. In the past week the stock fell -5.17%. stock has been down -10.70% in the past quarter and fell -16.60% in the past year. You can view this in the overview section.